Travere Therapeutics, Inc. reports developments in rare-disease biopharmaceuticals, with recurring updates on FILSPARI (sparsentan), FDA regulatory actions, commercialization in IgA nephropathy and focal segmental glomerulosclerosis, and financial results. The company focuses on therapies for rare kidney, liver, and metabolic diseases, including sparsentan and the investigational enzyme replacement therapy pegtibatinase.
Company news also covers clinical data presentations, partner-related regulatory and commercial milestones for sparsentan, capital-structure activity, inducement equity grants under Nasdaq rules, and investor-conference participation.
Travere Therapeutics (TVTX) management will participate in upcoming investor conferences, beginning with the Guggenheim Global Healthcare Conference on November 10, 2026.
Presentations follow at Stifel on November 11, UBS on November 16 and Jefferies London on November 17, 2026. Live webcasts will be accessible on the company’s Investor page, with replays available for up to 30 days following each event.
Travere Therapeutics (Nasdaq: TVTX) reported third-quarter FILSPARI U.S. net product sales of $200 million, up 120% year over year. Total U.S. net product sales rose to $220.2 million from $113.2 million. The quarterly net loss was $52.3 million, or $0.55 per basic share, versus net income of $25.7 million, or $0.29 per basic share. Results included a $113.1 million acquired research and development expense from the closed Everest Medicines civorebrutinib licensing agreement.
Cash, cash equivalents and marketable securities totaled $471.8 million at September 30, 2026. Travere expects Phase 3 pegtibatinase results in the second half of 2027 and plans a U.S. investigational new drug application for civorebrutinib by year-end. FILSPARI studies provided additional kidney-disease data. Bradley Campbell will succeed Eric Dube as CEO on December 1, 2026.
Travere Therapeutics (Nasdaq: TVTX) will report third quarter 2026 financial results on November 2, 2026, after U.S. financial markets close.
The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a general business update. An archived webcast will remain available on its website for 30 days.
Travere Therapeutics (TVTX) presented Phase 3 PROTECT biomarker results suggesting FILSPARI may modify underlying disease biology in IgA nephropathy.
The analysis included 295 of 404 adults in the randomized trial. At Week 110, urine-creatinine-normalized changes from baseline favored FILSPARI over maximum labeled dose irbesartan: sCD163 fell 60.1% versus 26.0%; BAFF fell 64.4% versus 45.2%; C5b-9 fell 50.2% versus 7.3%; and IL-6 fell 45.4% versus an 8.7% increase. These markers relate to immune activity and inflammation. Reported p values were nominal. Reductions occurred across measured time points through Week 110.
Previously reported PROTECT results showed greater reduction in urine protein and slower kidney function decline than irbesartan. Travere views the findings as supporting FILSPARI as an early, non-immunosuppressive treatment for IgA nephropathy.
Travere Therapeutics (TVTX) granted inducement equity awards covering 178,580 common shares to new employees on October 10, 2026.
The awards went to 33 employees and comprise options for 36,000 shares and restricted stock units (RSUs) covering 142,580 shares. Granted outside the 2018 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4), they remain subject to its terms. The options have a $52.02 exercise price and a 10-year term. Both award types vest over four years.
Travere Therapeutics (TVTX) will present new FILSPARI clinical data for two rare kidney diseases at ASN Kidney Week 2026. The program includes nine presentations, five oral, in Denver on October 21–25.
In the Phase 2 SPARTAN IgA nephropathy study, 75% achieved complete proteinuria remission, meaning very low urine protein, at any time during treatment. The least-squares mean change in estimated kidney filtration rate (eGFR) was −1.75 mL/min/1.73 m² at week 110.
A post hoc analysis of 254 patients with focal segmental glomerulosclerosis without nephrotic syndrome in Phase 3 DUPLEX found complete remission in 20% receiving FILSPARI versus 6% receiving maximum labeled dose irbesartan. Kidney failure occurred in 2% versus 8%, respectively. Treatment-emergent adverse event rates were comparable at 92% versus 94%.
Travere Therapeutics (TVTX) received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 19/253,120 covering certain methods of using FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS).
Upon issuance, the patent is expected to provide U.S. protection for these FSGS use methods into October 2037, following payment of the issue fee and standard post-allowance processing. Travere plans to submit the granted patent for listing in the FDA’s Orange Book. In August 2026, the company also obtained a separate U.S. patent covering certain methods of using sparsentan in IgA nephropathy (IgAN). The release reiterates FILSPARI’s approved U.S. indications and detailed safety information, including its boxed warnings and REMS requirements.
Travere Therapeutics (TVTX) announced a planned CEO transition, with Eric Dube stepping down and Bradley Campbell becoming president and chief executive officer on December 1, 2026.
Dube, who has led the company since January 2019, is leaving the CEO role to focus on his health and family and will remain employed as executive advisor through February 15, 2027 to support an orderly handover. Under his leadership, Travere gained regulatory approvals in IgA nephropathy and focal segmental glomerulosclerosis (including the first approved medicine for FSGS), expanded its rare disease pipeline and capabilities, and strengthened a patient-centered culture.
The Board unanimously selected Campbell, former president and CEO of Amicus Therapeutics (now a BioMarin subsidiary), citing his scientific, commercial and operational experience in rare diseases, his record of scaling therapies and advancing clinical pipelines, and his role in growing Amicus from a single-product to a multi-franchise global rare disease organization.
Travere Therapeutics (TVTX) will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.
A live webcast of the presentation will be available on the Investor page of Travere’s website at ir.travere.com/events-and-presentations, with a replay accessible for up to 30 days after the event.
Travere Therapeutics (TVTX) reported that on September 10, 2026, its Board Compensation Committee approved inducement restricted stock unit (RSU) awards for 16 new employees, covering a total of 56,220 shares of common stock. The RSUs, granted as employment inducements under Nasdaq Listing Rule 5635(c)(4), were made outside the company’s 2018 Equity Incentive Plan but are subject to its terms. The awards vest over four years, with 25% of the shares vesting on each anniversary of the grant date, contingent on continued service.